Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Autologous Skeletal Myoblasts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of coronary disease obtained by coronary angiography who require conventional aortocoronary bypass surgery.~* History of myocardial infarction with evidence of regional akinesis (or dyskinesia) for more than 4 weeks and less than 10 years.~* Ejection fraction from 25% to 45%.~* Evidence of no regional viability by dobutamine echocardiography.~* Aged from 30-80 years old.~* Negative serology to HIV, HBV and HCV.~* Patients without organ dysfunction.~* Negative pregnancy test (women of childbearing age).~* Informed consent granted.~Exclusion Criteria:~* History of myocardial infarction in the 4 weeks prior to the inclusion in the study.~* Prior history of tachycardia or ventricular fibrillation (except in patients with DAI device).~* History of cancer (except basocellular carcinoma) or prior treatment with chemotherapy.~* The patient should not suffer from any concomitant severe and/or uncontrolled medical condition.~* Patients who, due to their geographical, psychiatric or social status, have difficulties in meeting the conditions established in the protocol.~* Pregnant or beast feeding women.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Skeletal myoblasts (Type: EXPERIMENTAL): Patients who are receiving skeletal myoblasts
- Placebo (Type: PLACEBO_COMPARATOR): Revascularisation surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).